BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 37215110)

  • 21. Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
    Zhu Y; Liu K; Ding D; Zhou Y; Peng L
    Adv Ther; 2022 Jun; 39(6):2614-2629. PubMed ID: 35394255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma.
    Liu S; Dou L; Wang K; Shi Z; Wang R; Zhu X; Song Z; Li S
    Front Oncol; 2022; 12():899966. PubMed ID: 35936686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
    Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
    Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 29. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
    Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
    BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
    Kang S; Wang X; Pan Z; Liu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
    Liao W; Huang J; Hutton D; Li Q
    J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
    Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
    J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
    Long Y; Xu Y; Liao L; Zhou Y; Wang H
    BMJ Open; 2023 Aug; 13(8):e072106. PubMed ID: 37586861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer.
    Ye ZM; Xu Z; Wang HL; Wang YY; Chen ZC; Zhou Q; Li XP; Zhang YY
    Cancer Med; 2023 Mar; 12(5):6182-6189. PubMed ID: 36271484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.
    Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H
    Front Oncol; 2023; 13():1113346. PubMed ID: 37182176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
    Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
    Front Public Health; 2021; 9():743558. PubMed ID: 34957008
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
    Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
    Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
    Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
    Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
    Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.